Repligen Unveils Upcoming Second Quarter Results and Focus Areas

Repligen to Report Second Quarter 2025 Financial Results
Repligen Corporation (NASDAQ:RGEN) has announced that it will disclose its financial results for the second quarter of 2025. On Tuesday, July 29, 2025, before the market opens, the company will provide a detailed press release and host a conference call at 8:30 a.m. ET to share updates on business performance and discuss the financial results for the three- and six-month periods ended June 30, 2025.
How to Access the Conference Call
Investors and interested parties can join the conference call by dialing (800) 715-9871 for domestic calls, or (646) 307-1963 for international participants. No passcode is needed to participate in the live call. For those who prefer to watch the event online, a webcast will be available in the Investor Relations section of the company's website. In addition, the call and webcast will be archived for future reference. Replay options are also available, with dial-in numbers of (800) 770-2030 for U.S. callers and (609) 800-9909 for international callers. Remember to use the passcode 7706699 for accessing the replay.
About Repligen Corporation
Repligen Corporation is renowned for its leadership in the life sciences sector, specializing in the development and commercialization of innovative bioprocessing technologies. The company aims to enhance manufacturing efficiencies for biological drugs, serving a diverse range of clients, including biopharmaceutical developers and contract development and manufacturing organizations (CDMOs) on a global scale. Their areas of expertise encompass Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins. With its headquarters located in Waltham, Massachusetts, Repligen maintains several manufacturing facilities across the United States, along with significant operations in Europe, specifically in Estonia, France, Germany, Ireland, the Netherlands, and Sweden.
Further Information and Resources
To learn more about Repligen and its innovative technologies, please visit the company’s official website. For continuous updates and insights, follow Repligen on social media platforms.
Contact Information
Should you have any inquiries, reach out to:
Jacob Johnson
VP, Investor Relations
(781) 419-0204
investors@repligen.com
Frequently Asked Questions
1. When will Repligen report its second quarter 2025 results?
Repligen will announce its financial results on July 29, 2025.
2. What time does the conference call take place?
The conference call is set for 8:30 a.m. ET on the same day of the results announcement.
3. How can I access the conference call?
You can participate via phone or view the webcast. Dial (800) 715-9871 for domestic or (646) 307-1963 for international calls.
4. Where is Repligen Corporation headquartered?
Repligen Corporation is based in Waltham, Massachusetts.
5. How can I get more information about Repligen's technologies?
Visit the official Repligen website for detailed information about their innovative bioprocessing technologies.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.